Financial Snapshot
Revenues
Revenues
Revenue YoY Change
Revenues
Expenses
Cost Of Revenues
Gross Profit
Gross Profit Margin
Gross Profit
Selling, General & Admin Expense
Research & Development
Depreciation, Depletion & Amortization
SGA Expense to Gross Profit Ratio
R&D To Gross Profit Ratio
DDA To Gross Profit Ratio
Operating Expenses Total
Operating Profits/Loss
Operational Expenses
Interest Expenses
Interest Expenses To Operating Income %
Other Expense/Income
Interest & Other Expense/Income
Income/Loss
Pretax Income
Income Tax
Net Profits/Loss
Pretax Income YoY Change
Income Tax Rate
Net Profits/Loss YoY Change
Basic EPS
Net Income To Revenue Ratio
Pretax & Net Income
Assets & Liabilities
Cash & Short-Term Investments
Cash & Equivalents
Cash To Operating Expenses Ratio
Inventory
Receivables
Total Short-Term Assets
Property, Plant And Equipment
Long-Term Investments
Total Long-Term Assets
Total Assets
Net Income To Total Assets Percentage
Accounts Payable
Short-Term Debt
Long Term Debt Due
Total Short-Term Liabilities
Long-Term Debt
Other Long-Term Liabilities
Total Long-Term Liabilities
Total Liabilities
Short-Term To Long-Term Debt Ratio
Short-Term Assets To Debt Ratio
Long-Term Debt To Net Income Ratio
Assets & Liabilities
Ownership
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares
Stock Issuance & Repurchase
Ownership Data
Return On Shareholders' Equity
Book Value
Free Cash Flow
Free Cash Flow YoY
Free Cash Flow Margin
Dividends
Dividends
Stock Price
About ALPINE IMMUNE SCIENCES, INC.
Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. The company is headquartered in Seattle, Washington and currently employs 126 full-time employees. The company went IPO on 2015-06-17. The firm is focused on discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. The firm's scientific platform uses a directed evolution process to convert native immune system proteins from the immunoglobulin super family (IgSF) into multi-targeted therapeutics capable of modulating the human immune system. The Company’s product candidates include ALPN-101, ALPN-202 and ALPN-303. ALPN-101 is a dual inducible T cell costimulator (ICOS) and cluster of differentiation 28 (CD28) antagonist intended for the treatment of autoimmune and inflammatory diseases. Its oncology program is ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor intended for the treatment of cancer. ALPN-303 is a dual B-cell cytokine antagonist for the treatment of B-cell mediated diseases.
Industry: Pharmaceutical Preparations Peers: Aldeyra Therapeutics, Inc. MIMEDX GROUP, INC. Annexon, Inc. Biomea Fusion, Inc. BioXcel Therapeutics, Inc. CONCERT PHARMACEUTICALS, INC. Omega Therapeutics, Inc. Prelude Therapeutics Inc Tyra Biosciences, Inc.
